US Stock Insider Trading | Alkemes disclosed 4 insider transactions on February 6

K-LinePoet · 2026-03-07T12:54:18+00:00

Alkermes disclosed multiple insider transactions on February 6, 2026, including stock sales by four executives such as Jackson Blair Curtis. All transactions took place on February 5 and involved tens of thousands of shares, indicating active insider trading within the company.

K-LinePoet

2026-03-07 12:54:18

Abstract generation in progress

On February 6, 2026, Alkermes (ALKS) disclosed four insider transactions. Executive Jackson Blair Curtis sold 8,626 shares on February 5, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Executive	Jackson Blair Curtis	February 5, 2026	Sell	8,626	33.55	$289,400
February 6, 2026	Executive	Gaffin David Joseph	February 5, 2026	Sell	7,619	33.55	$255,600
February 6, 2026	Executive	Nichols Christian Todd	February 5, 2026	Sell	6,389	33.55	$214,400
February 6, 2026	Executive	Hopkinson Craig C.	February 5, 2026	Sell	7,454	33.55	$250,100
February 2, 2026	Director	Cooke Shane	February 2, 2026	Sell	29,000	34.34	$998,800
February 2, 2026	Executive	Hopkinson Craig C.	February 2, 2026	Buy	5,000	19.34	$96,700
February 2, 2026	Director	Cooke Shane	February 2, 2026	Buy	61,200	31.64	$1,936,400
February 2, 2026	Director	Cooke Shane	February 2, 2026	Sell	32,100	34.78	$1,116,900
February 2, 2026	Executive	Hopkinson Craig C.	February 2, 2026	Sell	4,000	33.54	$134,200
February 2, 2026	Executive	Hopkinson Craig C.	February 2, 2026	Sell	5,000	34.24	$171,200

[Company Information]

Alkermes Public Limited Company was incorporated in Ireland on May 4, 2011, as a private limited company named Antler Science Two Limited (Registration No. 498284). The company is a fully integrated global biopharmaceutical company that develops innovative medicines using its scientific expertise and proprietary technology to improve patient outcomes. The company has a diversified product portfolio, including over 20 marketed drugs and numerous clinical candidates for treating central nervous system disorders such as addiction, schizophrenia, and depression.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes